SBIR Phase I: Hypertension Treatment Responder Prediction

SBIR 第一阶段：高血压治疗反应预测

• 批准号: 0109801
• 负责人: Albert Man
• 金额: $ 9.92万
• 依托单位: PREDICTION SCIENCES, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2001-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0109801&HistoricalAwards=false
• 关键词: SBIR; Phase; Hypertension; Treatment; Responder

This Small Business Innovation Research (SBIR) Phase I project will develop the software platform, GeneRx, to incorporate pharmacogenetics and nonlinear adaptive algorithms toward optimizing anti-hypertension therapy on a patient specific basis. Preliminary studies on the psychotropic drug, olanzapine, show a 40% patient-by-patient error between predicted starting dose and optimal therapeutic dose, using a prototype trained only with patient chart information. This is a significant reduction from the range of starting doses for olanzapine currently used, which is from 1 to 80 mg/day. Anti-hypertensive drugs, like psychotropic drugs, have a large window of therapeutic options, including significant variation in dosages, medications, and combinations of therapies used. Using patient information and blood samples from a hypertension study done elsewhere, this Phase I project proposes to apply GeneRx to include genetic data in the modeling of hypertension treatment in combination with patient chart data. Genetic data for each patient will be acquired by genotyping DNA from the blood samples, scored as single nucleotide polymorphisms (SNPs) present or absent in key hypertension-related genes. GeneRx will take a patient's individual genetic, demographic, and environmental variables and predict if initial diuretic medication or initial beta-blocker medication will be effective. A more efficient method to prescribe effective anti-hypertension therapy would expedite recovery, minimize side effects, and reduce medical costs.The commercial application of this project will be in the field of healthcare management.

该小型企业创新研究（SBIR）第一阶段项目将开发软件平台GeneRx，以整合药物遗传学和非线性自适应算法，从而根据患者的具体情况优化抗高血压治疗。对精神药物奥氮平的初步研究显示，使用仅使用患者图表信息训练的原型，预测的起始剂量和最佳治疗剂量之间的患者误差为40%。这比目前使用的奥氮平起始剂量范围（1 - 80 mg/天）显著降低。抗高血压药物，如精神药物，有很大的治疗选择窗口，包括剂量，药物和所使用的治疗组合的显着变化。使用来自其他地方进行的高血压研究的患者信息和血液样本，该I期项目建议将GeneRx应用于高血压治疗建模中的遗传数据与患者图表数据相结合。将通过对血液样本中的DNA进行基因分型来获取每例患者的遗传数据，并根据关键高血压相关基因中存在或不存在的单核苷酸多态性（SNP）进行评分。GeneRx将采用患者的个体遗传、人口统计学和环境变量，并预测初始利尿剂药物或初始β受体阻滞剂药物是否有效。一个更有效的方法来制定有效的抗高血压治疗，将加快恢复，最大限度地减少副作用，并降低医疗成本，该项目的商业应用将在医疗管理领域。